Millennium Management LLC Acquires Shares of 122,619 BioVie Inc. (NASDAQ:BIVI)

Millennium Management LLC bought a new stake in BioVie Inc. (NASDAQ:BIVI) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 122,619 shares of the company’s stock, valued at approximately $245,000. Millennium Management LLC owned approximately 0.69% of BioVie as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. NewEdge Advisors LLC lifted its stake in shares of BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock worth $28,000 after acquiring an additional 14,000 shares during the period. Northern Trust Corp acquired a new stake in shares of BioVie in the 4th quarter worth approximately $34,000. Prosperity Wealth Management Inc. acquired a new stake in shares of BioVie in the 4th quarter worth approximately $63,000. Bank of Montreal Can acquired a new stake in shares of BioVie in the 4th quarter worth approximately $100,000. Finally, Geode Capital Management LLC lifted its stake in shares of BioVie by 223.3% in the 4th quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after acquiring an additional 85,234 shares during the period. Institutional investors and hedge funds own 4.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Brookline Capital Management raised shares of BioVie to a “strong-buy” rating in a research note on Tuesday, March 18th.

BioVie Stock Performance

BioVie stock opened at $1.11 on Thursday. The firm has a market cap of $20.61 million, a PE ratio of -0.11 and a beta of 0.77. The firm’s 50 day moving average price is $0.97 and its two-hundred day moving average price is $1.55. BioVie Inc. has a twelve month low of $0.62 and a twelve month high of $7.50.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.17.

BioVie Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.